Custom-Made vaccine takes on melanoma in early trial
NCT ID NCT04930783
First seen Mar 28, 2026 · Last updated Jun 23, 2026 · Updated 15 times
Summary
This early-phase trial tests a personalized vaccine called NeoVax, combined with an immune booster (CDX-301) and standard immunotherapy drugs (nivolumab or pembrolizumab), in 10 people with advanced melanoma. The goal is to see if the combination is safe and helps the immune system recognize and attack cancer cells. Because it's a phase 1 study, the main focus is on side effects and finding the right dose, not yet on curing the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
personalized neoantigen vaccine (NeoVax) plus CDX-301 and either nivolumab or pembrolizumab
What this could lead to
If this works, it could point toward a more effective treatment for advanced melanoma by training the immune system to attack cancer cells.
What could go wrong
This is a very early (phase 1) and small (10 people) trial focused on safety, not effectiveness. The personalized vaccine is complex and may not work for everyone.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.